Shaping the future of therapeutics

Today: Drug development processes are slow, inefficient, and cumbersome. Tomorrow: Advanced therapies are discovered, developed, and deployed using streamlined, reproducible processes. 

Increasing diversity in clinical trials, from pre-clinical through clinical stages, is essential to creating safe and effective therapeutics for everyone.  

From layering omics data onto images to connecting early-stage R&D data through clinical and commercial applications, the need to intelligently combine data modalities has never been greater.

Safe, effective drugs begin with high-fidelity models that set them up for the greatest possible success.

Trustworthy tools and processes are the cornerstone of enabling our customers’ most innovative ideas to become reality.  

Great ideas in biomedicine only matter if they reach patients. We help by streamlining manufacturing and helping ensure compliance and safety. 

Our depth and breadth of expertise—and customer relationships—across many kinds of instrumentation and data collection enables us to think beyond point solutions and toward workflows that solve broader challenges.

We pride ourselves on our track record of credibility across the life sciences space, from building the solutions that power the overwhelming majority of commercially available CAR-Ts, to creating the first high-fidelity and broadly available Cas-9 proteins, to pioneering the gold standard for AAV characterization. 

We are proud to partner with the world’s leading scientific minds through the Danaher Beacons program, identifying and solving challenges via applied research toward new product development. Our collaborations span disciplines to pioneer end-to-end solutions for our customers for maximum reliability and impact. 

Emerging genomic medicines face unique regulatory challenges. We work with our customers and collaborators, such as the Innovative Genomics Institute, to shape solutions that can increase access to these life changing medicines.